Samuel Lentz to Disease-Free Survival
This is a "connection" page, showing publications Samuel Lentz has written about Disease-Free Survival.
Connection Strength
0.042
-
Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol. 2003 Dec 01; 21(23):4350-5.
Score: 0.014
-
Thigpen JT, Blessing JA, Olt G, Lentz SS, Bell J. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Sep; 90(3):581-6.
Score: 0.014
-
Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Jun; 89(3):470-4.
Score: 0.014